局限性前列腺癌立体定向超分割MR引导放疗——前瞻性多中心SMILE II期试验的急性毒性与患者报告结局
前瞻性多中心II期SMILE试验纳入69例局限性前列腺癌患者,接受每日在线自适应MR引导立体定向体部放疗,处方37.5 Gy分5次隔日照射,可选同步加量至40 Gy。12周随访时未见CTCAE 3级及以上毒性,16例(23%)发生2级泌尿生殖或胃肠道毒性,12周时无残留2级泌尿生殖毒性、1例(1%)残留2级肠道症状。除情绪功能评分显著改善外,整体健康状况及相关子评分无临床有意义变化。
要点
- 69例局限性前列腺癌接受MR引导每日在线自适应SBRT,37.5 Gy分5次隔日照射。
- 12周随访未见CTCAE 3级及以上毒性,16例(23%)发生2级泌尿生殖或胃肠道毒性。
- 12周时无残留2级泌尿生殖毒性,1例(1%)残留2级肠道症状。
核心结论
- 每日在线自适应MRgSBRT治疗局限性前列腺癌总体毒性反应极好,对生活质量无重大负面影响。
研究设计与样本
- 前瞻性、多中心II期SMILE试验,纳入69例局限性前列腺癌患者。
- 患者接受MR引导立体定向体部放疗(MRgSBRT)并每日在线自适应计划。
- 纳入标准为肿瘤分期≤T3a、血清PSA≤20 ng/ml、ISUP分级分组≤4。
- 处方剂量37.5 Gy分5次隔日照射至PTV,可选对多参数MRI定义的前列腺内优势病灶同步加量至40 Gy。
- 按CTCAE v5.0和RTOG标准评估急性泌尿生殖(GU)和胃肠道(GI)毒性,并按EORTC QLQ-C30和QLQ-PR25量表分析患者报告结局,在放疗结束时、放疗后6周和12周与基线症状比较。
主要发现
- 无因毒性终止治疗者。
- 12周随访时按CTCAE未报告3级及以上毒性。
- 截至12周随访,共16例(23%)经历2级GU或GI毒性。
- 毒性发生率在放疗结束时达峰,并在12周随访期内消退。
- 12周随访时无残留2级GU毒性,1例(1%)有残留2级肠道症状。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to superior image quality and daily adaptive planning, MR-guided stereotactic body radiation therapy (MRgSBRT) has the potential to further widen the therapeutic window in radiotherapy of localized prostate cancer. This study reports on acute toxicity rates and patient-reported outcomes after MR-guided adaptive ultrahypofractionated radiotherapy for localized prostate cancer within the prospective, multicenter phase II SMILE trial. MATERIALS AND METHODS: A total of 69 patients with localized prostate cancer underwent MRgSBRT with daily online plan adaptation. Inclusion criteria comprised a tumor stage ≤ T3a, serum PSA value ≤ 20 ng/ml, ISUP Grade group ≤ 4. A dose of 37.5 Gy was prescribed to the PTV in five fractions on alternating days with an optional simultaneous boost of 40 Gy to the dominant intraprostatic lesion defined by multiparametric MRI. Acute genitourinary (GU-) and gastrointestinal (GI-) toxicity, as defined by CTCAE v. 5.0 and RTOG as well as patient-reported outcomes according to EORTC QLQ-C30 and -PR25 scores were analyzed at completion of radiotherapy, 6 and 12 weeks after radiotherapy and compared to baseline symptoms. RESULTS: There were no toxicity-related treatment discontinuations. At the 12-week follow-up visit, no grade 3 + toxicities were reported according to CTCAE. Up until the 12-week visit, in total 16 patients (23 %) experienced a grade 2 GU or GI toxicity. Toxicity rates peaked at the end of radiation therapy and subsided within the 12-week follow-up period. At the 12-week follow-up visit, no residual grade 2 GU toxicities were reported and 1 patient (1 %) had residual grade 2 enteritic symptoms. With exception to a significant improvement in the emotional functioning score following MRgSBRT, no clinically meaningful changes in the global health status nor in relevant subscores were reported. CONCLUSION: Daily online-adaptive MRgSBRT for localized prostate cancer resulted in an excellent overall toxicity profile without any major negative impact on quality of life.
引用
- Fink CA, Ristau J, Buchele C, et al. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial. Clin Transl Radiat Oncol. 2024. PMID: 38586081. doi:10.1016/j.ctro.2024.100771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。